MetalloBio are Awarded a £30k CPI Health Tech Regulatory Support Grant
MetalloBio has been awarded £30,000 in non-dilutive funding from CPI and Innovate UK as part of the CPI Health Tech Regulatory Support Programme.
The funds will be used to conduct a regulatory gap analysis of MetalloBio’s antimicrobial platform technology. The gap analysis conducted by TranScrip will involve a detailed analysis of MetalloBio’s technical and regulatory development pathway to identify gaps in the development plan. This will de-risk MetalloBio’s development plan and regulatory strategy and accelerate the technology’s time to market.
Additionally, it will facilitate further work with MetalloBio and TranScrip to fully map out the regulatory strategy for MetalloBio’s systemic antimicrobial and medical device coating technologies.
The £7 million funding programme supported by CPI and ABHI is a joint initiative funded by Innovate UK to support small- and medium-sized health technology companies navigate the HealthTech regulatory processes.
The UK’s regulator landscape for health technologies is changing, and companies need to prepare for a UK sovereign regulatory system, with the Medicines and Healthcare Regulatory Agency, MHRA, currently consulting on the future regulation of medical devices and in vitro diagnostics in the UK. Additionally, MetalloBio will target EU markets, and therefore will need to adhere to the new MDR regulations.
Based in Sheffield, South Yorkshire, MetalloBio is focussing on the development of a novel antimicrobial platform technology to treat and prevent pathogenic, multi-drug resistant, Gram-negative bacterial infections. Antimicrobial resistance (AMR) is a global health threat. Currently, AMR is responsible for 700,000 annual fatalities, it is predicted by 2050 this could rise to 10 million deaths per year costing a £66 trillion loss to the global economy.
Kirsty Smitten, CEO of MetalloBio, said: “We are really happy to have secured this funding, we are currently in the preclinical stage of the technologies development and this funding will allow us to work closely with TranScrip to map out our regulatory pathway.”
For further information contact:
MetalloBio Limited
Kirsty Smitten
email: kirsty.smitten@metallobio.com